Anne Li 6/30/2017 email@example.com
Treatments that harness the power of the immune system against cancer are an exciting area that’s seen an explosion of interest and developments in recent years. A number of these immunotherapy drugs have now been approved in the UK for several different cancers. And trials are underway that could open them up to even more cancer types in the future. Those that are already approved have had impressive results in some people with advanced disease. But there’s an issue. The drugs don’t work for everyone. What is it about the immune systems and tumours of those who do respond well to the treatments that separates them from those who don’t? That’s a question Professor Christian Ottensmeier, a Cancer Research UK-funded immunotherapy expert at the University of Southampton, and Professor Pandurangan Vijayanand, from the University of Southampton and the La Jolla Institute for Allergy and Immunology in the US, set out to discover.
See original article at: http://scienceblog.cancerresearchuk.org/2017/06/27/lung-cancer-discovery-points-to-a-better-way-to-personalise-immunotherapy/